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ABSTRACT
Background/aims To evaluate the cost-effectiveness of
ranibizumab as either monotherapy or combined with
laser therapy, compared with laser monotherapy, in the
treatment of diabetic macular oedema (DME) causing
visual impairment from a UK healthcare payer
perspective.
Methods A Markov model simulated long-term outcomes
and costs of treating DME in one eye (BCVA #75 letters)
based on data from the RESTORE Phase III trial. Outcomes
measured in quality-adjusted life-years (QALYs) were
simulated for a 15-year time horizon based on 12-month
follow-up from RESTORE and published long-term data.
Costs included treatment, disease monitoring, visual
impairment and blindness (at 2010 price levels).
Results Ranibizumab monotherapy resulted in a 0.17
QALY gain at an incremental cost of £4191 relative to
laser monotherapy, yielding an incremental cost-
effectiveness ratio (ICER) of £24028. Probabilistic
sensitivity analysis showed a 64% probability of being
cost-effective at a threshold of £30000 per QALY.
Combined ranibizumab and laser therapy resulted in
a 0.13 QALY gain at an incremental cost of £4695 relative
to laser monotherapy (ICER £36106; 42% probability of
ICER <£30000).
Conclusions Based on RESTORE 1-year follow-up data,
ranibizumab monotherapy appears to be cost-effective
relative to laser monotherapy, the current standard of
care. Cost-effectiveness of combination therapy is less
certain. Ongoing studies will further inform on disease
progression and the need for additional ranibizumab
treatment.
INTRODUCTION
Diabetic macular oedema (DME) is the most
frequent cause of vision impairment in people with
diabetes and can lead to blindness if left untreated.
Even when patients receive optimal treatment
with the current standard of care for DME, laser
photocoagulation, improvements in vision are
relatively uncommon and many patients lose vision
despite laser therapy.
1 2 This continued vision loss
is the result of structural and physiological damage
to the retinal capillary bed, and from progressive
and permanent damage to the macular pigment
epithelium, associated with poor control of blood
glucose, blood pressure and lipid levels (the three
main systemic risk factors for diabetic retinopathy
and DME).
3
The UK prevalence of visual impairment due to
DME is estimated at approximately 3% of the adult
(aged 18+ years) diabetic population.
4 Visual
impairment places a substantial socio-economic
burden on patients, their caregivers and healthcare
systems at large.
5 There is, therefore, a strong
public health incentive to choose safe therapies that
provide increased health gains through improved
vision and patient functioning, while offering an
acceptable balance between beneﬁts and costs.
Ranibizumab (Lucentis
, Novartis Pharma AG,
Switzerland) is a novel agent that is currently
licensed for the treatment of visual impairment due
to DME.
6 Ranibizumab selectively inhibits active
isoforms of human vascular endothelial growth
factor A (VEGF-A) from binding to its receptors.
VEGF-A stimulates growth of new blood vessels
and is a major mediator of increased vascular
leakage,
7e10 mechanisms thought to be associated
with retinal damage and progression of DME and
the resulting visual impairment.
The Phase III RESTORE trial enrolled 345
patients with visual impairment due to DME and
assessed ranibizumab given either as monotherapy
or in combination with laser photocoagulation,
compared with laser photocoagulation alone. The
results showed that ranibizumab alone or in
combination with laser provided signiﬁcantly
greater improvements in best corrected visual
acuity (BCVA) at 1 year compared with laser
therapy alone, with mean average BCVA changes of
+6.1 and +5.9 versus +0.8 letters, respectively.
11 In
addition, health-related quality of life, as assessed
using the National Eye Institute Visual Function
Questionnaire (NEI VFQ-25), was improved
signiﬁcantly from baseline for both ranibizumab
treatment groups compared with laser therapy
alone (p<0.05 for composite score and vision-
related subscales). RESTORE is ongoing in a 2-year
open-label extension phase.
This report summarises the results of a health
economic model that was developed based on
RESTORE trial data to evaluate the cost-effective-
ness of ranibizumab from a UK payer perspective
when used as monotherapy or in combination with
laser therapy compared with laser therapy alone.
The model was developed separately from current
assessments of ranibizumab by the UK Health
Technology Assessment bodies, such as the National
Institute for Health and Clinical Excellence.
METHODS
A Markov model was constructed to simulate
costs and changes in BCVA over a 15-year period in a
hypothetical cohort of patients with DME (ﬁgure 1),
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Clinical sciencebased on data from the RESTORE trial (in which 87.5% of
patients had type 2 diabetes and average baseline glycated
haemoglobin was 7.3%). The average age at entry to the model
was 63 years, consistent with patient characteristics in
RESTORE. The model also assumed the same baseline BCVA
distribution, but excluded patients with BCVA >75 letters,
consistent with guidance from the ranibizumab summary of
product characteristics that such patients may beneﬁtl e s sf r o m
treatment than those with baseline BCVA #75 letters.
6
The model framework allocated eight linear health states
deﬁned by BCVA in the treated eye using a set of 10-letter (two-
line) categories (table 1). Movement of patients from one health
state to another was determined by transition probabilities that
depended on the effectiveness of treatment and natural BCVA
changes over time. A 10-letter range was used to categorise
health states based on evidence that a 10-letter BCVA score loss
is associated with a substantial decline in health-related quality
of life (eg, loss of functional ability, increasing dependency, role
limitations and impaired mental health).
15 Each health state was
assigned a quality-of-life index and cost. Costs and outcomes
were accrued over 3-month cycles, applying half-cycle correc-
tions. The time horizon in the base case was 15 years; although
a lifetime horizon could be justiﬁed given the chronic nature of
the condition, we selected a more conservative approach for the
base case because of the lack of evidence on long-term prognosis.
The key inputs and assumptions are summarised in table 2.
Patients were assumed to receive ranibizumab treatment in year
1 at the frequency observed in RESTORE. In year 2, patients
were assumed to need fewer injections, as observed in the
Diabetic Retinopathy Clinical Research Network (DRCR.net)
protocol I study (which included patients with comparable
baseline demographics to RESTORE).
1 A proportionately
smaller number of monitoring visits was therefore assumed in
year 2. After year 2, laser therapy was assumed to be adminis-
tered as required in all arms, with no further need for ranibi-
zumab; the assumed number of monitoring visits was further
reduced accordingly.
The average BCVA achieved in year 1 was assumed to be
maintained during year 2, as was observed in the DRCR.net
protocol I study.
1 After year 2, all arms of the model followed
natural disease history based on 4-year health state transition
outcomes modelled from the Wisconsin Epidemiologic Study of
Diabetic Retinopathy (WESDR) reports.
17e19 Transition proba-
bilities were calibrated to adjust for the improvement in diabetes
management since the WESDR reports (see Supplementary
Methods), and predicted that around 30% of patients would be
expected to exhibit a worsening in BCVA of at least 10 letters
and 20% of patients would show an improvement of at least 10
letters over a 4-year time horizon (Supplementary table 1).
Treatment discontinuation rates observed in RESTORE were
applied to the model in year 1; it was assumed there would be no
additional withdrawals from treatment in year 2. Adverse events
were assumed to have a negligible impact on the cost-effec-
tiveness of ranibizumab therapy based on the established safety
proﬁle of ranibizumab in clinical trials in DME and in wet age-
related macular degeneration, an indication for which ranibi-
zumab is also licensed.
1 20e22
Mortality was estimated by adjusting general UK population
death rates according to the increased RR of death in patients
with DME. Mulnier et al estimated an increased mortality (HR
1.93) in a UK type 2 diabetes population relative to patients
without diabetes,
23 while Hirai et al estimated an HR of 1.27 for
death in patients with clinically signiﬁcant macular oedema
(CSME) and diabetes relative to diabetic patients without
CSME.
24 We calculated a 2.45 RR of death in a DME population
by multiplying these two ratios.
BCVA 86–100 letters
RESTORE patient
baseline characteristics
(BCVA 39–75 letters)
BCVA 76–85 letters
BCVA 66–75 letters
BCVA 56–65 letters
BCVA 46–55 letters
BCVA 36–45 letters
BCVA 26–35 letters
Death
Blindness (UK definition)
Figure 1 Markov model structure. Health states are deﬁned by best
corrected visual acuity (BCVA) in the treated eye. Patients enter the
model at treatment start where they are assumed to have BCVA as in
RESTORE (>39 letters and #75 letters). BCVA is evaluated at 3-monthly
intervals. After each cycle, patients may transition to any other health
state including death; the probability of moving from health state A to
health state B is based on RESTORE data (baseline to month 12) and
literature.
Table 1 Utility by BCVA in treated eye
Health state deﬁned
by BCVA category
(letters; treated eye)
RESTORE* Lloyd et al
12 y Brown et al
13 x
Mean utility (SE)
1: 86e100 0.860 (0.034)z 0.830 0.839
2: 76e85 0.860 (0.014) 0.750 0.839
3: 66e75 0.813 (0.012) 0.750 0.783
4: 56e65 0.802 (0.014) 0.715 0.783
5: 46e55 0.770 (0.018) 0.680 0.732
6: 36e45 0.760 (0.027) 0.680 0.681
7: 26e35 0.681 (0.053) 0.530 0.630
8: 0e25 0.547 (0.083) 0.340 0.579
*Utility scores were calculated based on EQ-5D scores in RESTORE; EQ-5D scores were
converted to utilities using social tariffs measured in a UK population.
14 Mean utility for each
BCVA state was calculated using a regression technique for repeated measurements at
baseline, month 3, month 6 and month 12. Data from several measurement points were
pooled to cover all possible health state transitions with a sufﬁcient sample size. A possible
trend effect in the pooled data was rejected (p<0.05).
yPatients underwent a Snellen visual acuity (VA) assessment and were categorised based
on the better-seeing eye. Some adjustments were made to published values in order to
convert VA ranges in Lloyd et al (obtained in a population of patients with diabetic
retinopathy) to health states as deﬁned in the current model.
xUtilities were elicited from patients with diabetic retinopathy. Patients underwent
a Snellen VA assessment and were categorised based on the better-seeing eye. Some
adjustments were made to published values in order to convert VA ranges to health states
as deﬁned in the current model.
zRestricted to being greater than or equal to the utility in health state 2.
BCVA, best corrected visual acuity.
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Clinical scienceUtility scores were calculated based on patient-reported
outcomes data from RESTORE (table 2), in which patients
completed the EuroQoL (EQ-5D) questionnaire at baseline and
months 3, 6 and 12. Individual EQ-5D health scores were
converted into utility scores using preferences from a UK
population survey;
14 mean utility scores were calculated for each
health state (table 1). As these states were deﬁned by BCVA in
the treated eye, of which 67.2% were the worse-seeing eye at
baseline, this method established an association between utility
and BCVA changes in the treated eye.
Health state costs included the costs of treatment and
monitoring (Supplementary tables 3e6), and the costs associ-
ated with blindness (Supplementary table 2). Treatment costs
included the costs of ranibizumab (Novartis UK, personal
communication) and its administration, laser therapy and
investigative procedures. Monitoring costs, including consulta-
tion and procedure costs, were estimated from the UK National
Health Service Reference Costs.
25 Costs of blindness included
those incurred by the UK National Health Service for items such
as low-vision aids, low-vision rehabilitation, residential or home
care, depression and hip fracture/replacement as listed in the
costing study by Meads and Hyde.
16 Where older cost estimates
were used, these were inﬂated to 2010 prices using the Hospital
and Community Health Services index.
26 The cost of blindness
would be incurred only in patients reaching health states with
BCVA #35 letters (Snellen #6/60) in the better-seeing eye.
However, as the study assesses treatment response according to
the enrolled eye, the proportion of patients reaching this level
within the time horizon of the model is therefore uncertain. As
such, the base case model adjusts for the cost of blindness on the
basis of treated eyes reaching the BCVA #35-letter threshold. As
with other model parameters subject to uncertainty, deviations
from this assumption were explored in sensitivity analyses
(Supplementary table 7).
The main outcome measure was the incremental cost-
effectiveness ratio (ICER), expressed as the additional cost per
quality-adjusted life-year (QALY) gained by one treatment over
another. An annual 3.5% discount rate was applied for future
costs and utilities, consistent with the standard UK approach.
Univariate sensitivity analyses assessed the uncertainty
around speciﬁc data sources by exploring the effects on the ICER
of inputs, as shown in table 3. Probabilistic sensitivity analysis
assessed the overall uncertainty about the ICER based on vari-
ations in individual input parameters; details of the applied
distributions and results are provided in Supplementary table 7.
RESULTS
The model predicted that after 1 year, a greater proportion of
patients treated with ranibizumab monotherapy or combination
therapy would have BCVA >65 letters (Snellen score >6/18)
compared with patients treated with laser monotherapy (48%
and 47%, respectively, versus 38% in the laser arm) (ﬁgure 2).
After 15 years, the proportion with severe visual impairment in
the treated eye (BCVA <35 letters, Snellen <6/60) was predicted
to be 12% and 13% in the ranibizumab monotherapy and
combination therapy groups, respectively, versus 19% in the
laser group.
Ranibizumab monotherapy was associated with an incre-
mental gain of 0.17 QALY and cost of £4 191, corresponding to
an ICER of £24028 per QALY gained relative to laser mono-
therapy (table 3). Combination therapy provided an incremental
gain of 0.13 QALY over laser monotherapy for an incremental
cost of £4 695, leading to an ICER of £36106 per QALY gained.
Univariate sensitivity analyses showed that the model was
stable and that ICERs were most sensitive to changes in the
number of injections and time horizon (table 3). Using utilities
elicited by Lloyd et al
12 and Brown et al
13 in patients with dia-
betic retinopathy led to greater QALY gains and lower ICERs for
ranibizumab monotherapy or combination therapy relative to
laser monotherapy. Probabilistic sensitivity analysis conﬁrmed
the model’s robustness (Supplementary ﬁgure 1). Assuming
a willingness-to-pay threshold of £30000 per QALY gained, the
Table 2 Key model inputs and assumptions
Time period Model input Combination therapy Ranibizumab monotherapy Laser monotherapy Source
Year 1 BCVA progression RESTORE trial data,
adjusted for drop-out rates
RESTORE trial data, adjusted
for drop-out rates
RESTORE trial data,
adjusted for drop-out rates
RESTORE data on ﬁle
Treatment frequency 7 injections + 2 laser
sessions, as in RESTORE;
drop-outs continue in
standard care (ie, laser therapy)
7 injections; drop-outs
continue in standard care
(ie, laser therapy)
2 laser sessions; drop-outs
continue in standard care
(ie, laser therapy)
RESTORE data on ﬁle
Monitoring visits 12 12 4 SmPC and expert interview
(data on ﬁle)
Adverse events Negligible Negligible Negligible RESTORE data on ﬁle
Year 2 BCVA progression Equal rates of improvement
and worsening (3% in 3 months)
Equal rates of improvement
and worsening (3% in 3 months)
Equal rates of improvement
and worsening (3% in 3 months)
Supported by DRCR.net
and RESTORE data on ﬁle
Treatment frequency 2 injections + 1 laser session 3 injections (no laser) 1 laser session Supported by DRCR.net
Monitoring visits 8 10 4 Assumption
Year 3 BCVA progression Constant rates of change of
BCVA with a majority of
patients having a decline
in BCVA
Constant rates of change
of BCVA with a majority
of patients having a decline
in BCVA
Constant rates of change
of BCVA with a majority of
patients having a decline
in BCVA
Calibrated to WESDR data
(Supplementary Methods)
Treatment frequency No additional ranibizumab;
laser therapy as required
No additional ranibizumab;
laser therapy as required
Laser therapy as required Assumption
Monitoring visits 4 4 4 Assumption
Any year Cost of blindness When BCVA #35 letters is
reached in better-seeing eye
When BCVA #35 letters is
reached in better-seeing eye
When BCVA #35 letters is
reached in better-seeing eye
Adapted from costing
approach by Meads et al
16
(Supplementary table 2)
Patient-level changes in BCVA data in RESTORE were used to derive transition probabilities in year 1.
After year 1, long-term changes in BCVA were simulated assuming categorisation into one of three possible outcomes: $10 letters improvement within 3 months (one health state up), $10
letters worsening within 3 months (one health state down) or no change exceeding 10 letters within 3 months.
BCVA, best corrected visual acuity; DRCR, Diabetic Retinopathy Clinical Research Network; SmPC, summary of product characteristics; WESDR, Wisconsin Epidemiologic Study of Diabetic
Retinopathy.
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Clinical scienceprobability that ranibizumab monotherapy would be cost-
effective relative to laser monotherapy was estimated to be 64%
(Supplementary ﬁgure 2); the corresponding probability for
combination therapy relative to laser monotherapy was 42%.
DISCUSSION
This is the ﬁrst study to evaluate the cost-effectiveness of an
anti-VEGFagent for the treatment of patients with DME causing
visual impairment. Our economic model, which was based on
data from the RESTORE clinical trial, shows that ranibizumab
monotherapy provides superior improvements in visual acuity
and is cost-effective relative to the current standard of care, laser
photocoagulation. Ranibizumab monotherapy was associated
with an ICER of £24028 per QALY gained relative to laser
therapy alone, a value within the willingness-to-pay threshold of
£30000 per QALY gained that has generally been considered cost-
effective in the UK. The results of our model may be applicable
to a broad spectrum of patients with visual impairment due to
DME, as the RESTORE trial showed consistent efﬁcacy of
ranibizumab therapy across patient subgroups based on a range
of demographic and disease characteristics.
The cost-effectiveness of combined ranibizumab and laser
therapy was less favourable than that of ranibizumab mono-
therapy (ICER £36106 per QALY gained relative to laser therapy
alone). While this in part reﬂects higher treatment costs,
combination therapy also provided a lower predicted QALY gain
than ranibizumab monotherapy (0.13 vs 0.17 QALYover the 15-
year time horizon in the base case). A possible explanation for
these results is the observation in RESTORE that combination
therapy provided smaller improvements in BCVA in patients
who had received prior laser therapy than those who had not
(4.7 vs 6.9 letters gained, respectively).
11 In RESTORE, the
proportions of patients who received prior laser therapy were
52% (ranibizumab monotherapy), 47% (combination therapy)
and 43% (laser therapy).
Sensitivity analyses showed that the model results were
robust to reasonable alterations in inputs and assumptions;
ICERs were particularly sensitive to changes in the number of
ranibizumab injections and the time horizon of the model. The
base case assumed an average of 10 ranibizumab injections over
2 years, based on data from the DRCR.net protocol I study.
1
Ranibizumab monotherapy remained cost-effective (ICER
below £30000 per QALY gained) up to a total of 13 injections.
Increasing the number of injections beyond 13 resulted in an
ICER outside the generally accepted threshold, emphasising that
additional injections beyond 2 years of treatment will be an
important cost driver. However, the current model is conserva-
tive in that it includes incremental costs for additional injections
beyond year 2, but assumes no incremental beneﬁt. The possible
need for re-treatment beyond 2 years remains speculative;
forthcoming data from the 2- and 3-year RESTORE follow-up
and the DRCR.net 5-year data will improve our understanding
of the likely duration of treatment. Longer time horizons would
be expected to lead to improved cost-effectiveness of ranibi-
zumab, because the beneﬁts of improved vision accrue over time
whereas treatment costs are incurred immediately once treat-
ment is initiated.
We have identiﬁed only one previously reported cost-effec-
tiveness study of interventions for DME. Sharma et al modelled
the cost-effectiveness of laser therapy alone for DME,
27
comparing early and deferred laser treatment with no treatment
based on 3-year outcomes from the Early Treatment Diabetic
Retinopathy Study.
28 The model included health states deﬁned
by BCVA and applied a 40-year time horizon based on a popu-
lation with a mean age of 47 years. Over this time horizon, laser
treatment was predicted to provide a gain of 0.236 QALY and
was considered highly cost-effective for DME relative to no
treatment. Our results cannot be compared directly with the
Sharma et al
27 study because RESTORE did not include a ‘no
treatment’ arm; moreover, our model applied a 15-year time
Table 3 Cost-effectiveness: base case and sensitivity analyses*
Assumption/parameter Base case Sensitivity analyses Incremental cost Incremental QALY ICER ICER (% change)
Ranibizumab monotherapy versus laser monotherapy
Base case ee £4191 0.17 £24028 e
Discount rate of future costs
and beneﬁts
3.50% 0%e5% £3593e£4383 0.16 to 0.16 £17051e£27042 e29% to +13%
Time horizon 15 years 10e20 years £4738e£3991 0.14 to 0.19 £33139 to £21343 +38% to e11%
Cost of blindness £6477 e25% to +25% £4868e£3515 0.17 to 0.17 £27907e£20150 +16% to e16%
Long-term progression of VA Declining Constant or increasing £4487e£4693 0.17 to 0.17 £26198e£28413 +9% to +18%
Total number of ranibizumab
injections
10 e4 injections to +4 injections £2171e£6774 0.17 to 0.17 £12446e38836 e48% to +62%
Baseline age 63 years 58 years £3767 0.20 £19259 e20%
Source of utilities RESTORE Lloyd et al
12 £4191 0.22 £19238 e20%
RESTORE Brown et al
13 £4191 0.19 £21953 e9%
Combination therapy versus laser monotherapy
Base case ee £4695 0.13 £36106 e
Discounting of future costs
and beneﬁts
3.50% 0%e5% £4271e£4828 0.16 to 0.12 £26957e£40096 e25% to +11%
Time horizon 15 years 10e20 years £5133e£4507 0.10 to 0.13 £49294e£34135 +37% to e5%
Cost of blindness £6477 e25% to +25% £5050e4340 0.13 to 0.13 £38833e£33378 +8% to e8%
Long-term progression of VA Declining Constant or increasing £5091e£5276 0.13 to 0.12 £40852e£44071 +13% to +22%
Total number of ranibizumab
injections
9 e4 injections to +4 injections £3165e£7260 0.13 to 0.13 £24340e£55828 e33% to +55%
Baseline age 63 years 58 years £4393 0.15 £29952 e17%
Source of utilities RESTORE Lloyd et al
12 £4695 0.16 £28778 e20%
RESTORE Brown et al
13 £4695 0.16 £29576 e18%
*Incremental cost measures the additional cost of ranibizumab monotherapy or combination therapy compared with laser monotherapy in the modelled time horizon (15 years in base case).
Incremental QALY measures the corresponding QALY gain when ranibizumab monotherapy or combination therapy is compared with laser monotherapy. The ICER is calculated by dividing the
incremental cost by the incremental QALY. The ICER is interpreted as the cost of achieving an additional year of life in perfect health.
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; VA, visual acuity.
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Clinical sciencehorizon from a baseline age of 63 years, consistent with
RESTORE. However, if a baseline age of 47 years and time
horizon of 40 years were applied to our model, as in the Sharma
et al
27 model, the RESTORE model would predict a 0.26 QALY
gain and an ICER of £10412 for ranibizumab monotherapy
relative to laser therapy alone. This suggests that the cost-
effectiveness of ranibizumab would be higher in patients with
DME who were younger than the average in RESTORE
(63 years) because of their longer life expectancy.
Several methodological considerations should be noted. While
treatment effectiveness was based on 1-year data from
RESTORE, we projected long-term changes in BCVA using the
best available clinical evidence. For year 2, the DRCR.net
protocol I study supported the assumption that BCVA at 1 year
was maintained on average to 2 years.
1 BCVA changes in years
3e15 were based on reported progression in the WESDR study,
which demonstrated a gradual decline in vision over time in
DME. The rate of decline in BCVA was reduced by adjustment
using data from both the Diabetes Control and Complications
Trial and UK Prospective Diabetes Study to account for a less
intensive systemic diabetes management regimen in the past
relative to current practice.
29e32 Sensitivity analysis showed
that these assumptions had only a minor impact on the model
results.
Utilities were estimated from the BCVA of treated eyes in
RESTORE, irrespective of whether this was the better-seeing or
worse-seeing eye. This approach links utility values directly to
the eye receiving the intervention. The RESTORE study
protocol required the worse-seeing eye to undergo intervention
unless there was a medical contraindication; 32.8% of treated
eyes were the better-seeing eye at baseline, and 37.3% were the
better-seeing eye at 12 months. Using the better eye as refer-
ence is supported by quality of life studies in vision-related
conditions, which have shown that the better eye is the major
driver of overall quality of life and patient functioning.
33
Indeed, patient-preference studies have shown that the utility
gains associated with treating the worse-seeing eye are uncer-
tain, even though good vision in two eyes confers better
quality of life than good vision in only one eye.
34 As expected,
subdividing the elicited utilities in RESTORE by better-seeing
or worse-seeing eye showed that patients being treated in the
better-seeing eye reported lower utility at a given level of
BCVA than those treated in the worse-seeing eye. Nevertheless,
utility measured in patients treated in the worse-seeing eye
demonstrated signiﬁcant sensitivity to variation in the BCVA
in the treated eye, comparable with that of patients treated in
the better-seeing eye. Unfortunately, the small sample of
RESTORE patients in each BCVA health state meant that the
resulting utility functions were not sufﬁciently robust to allow
separate cost-effectiveness analysis by better-seeing or worse-
seeing eye. It should also be stated that the option of not
treating visual impairment in a better-seeing eye is not an
ethical stance.
We could not ﬁnd published utility estimates from speciﬁc
populations with DME. We performed sensitivity analysis using
utilities reported in two studies based on populations with
diabetic retinopathy (which includes a wider population than
DME).
12 13 Lloyd et al reported utilities elicited by the general
population, while Brown et al reported utilities elicited by
patients. This showed that applying the Lloyd et al
12 utilities to
the model greatly improved the cost-effectiveness of ranibi-
zumab monotherapy, leading to a larger incremental gain of 0.22
QALY and a lower ICER of £19238 per QALY gained relative to
laser therapy alone. Applying the Brown et al
13 utilities also
increased the QALY gain with ranibizumab and led to an ICER
of £21953 per QALY gained for ranibizumab monotherapy
versus laser therapy alone. The fact that the RESTORE utilities
are less sensitive to BCVA decline may simply reﬂect the fact
that a majority of the reference eyes in RESTORE were worse-
seeing, while all reference eyes in the Lloyd et al
12 and Brown
et al
13 studies were better-seeing.
Limitations of this analysis should be considered. First, we
modelled treatment of unilateral DME based on RESTORE data,
but did not estimate the cost-effectiveness of treating bilateral
DME. While 82.8% of patients in RESTORE had signs of bilat-
eral DME at baseline, the proportion of patients who would
have become eligible for treatment because of vision impairment
in their fellow eye was not known. Treatment of both eyes may
be relevant in many patients with bilateral DME, but there is
a lack of evidence for the additional utility beneﬁt of treating the
fellow eye. Uncertainty also exists regarding the cost conse-
quences of treating both eyes, where total cost is not likely
to double given the possibility of achieving economies of scale
from shared categorical spending, such as administrative and
monitoring costs. An additional limitation was that the model
assumed the cost of blindness would be incurred in patients
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Figure 2 Modelled distribution by health states after (A) 1 and (B)
15 years. BCVA, best corrected visual acuity.
692 Br J Ophthalmol 2012;96:688e693. doi:10.1136/bjophthalmol-2011-300726
Clinical sciencereaching health states with BCVA #35 letters (Snellen #6/60) in
the treated eye.
There is also uncertainty inherent in working with published
results of studies, as was necessary for incorporating the DRCR
Network Protocol I results, as opposed to using patient-level
data. While analysis using patient level data is clearly preferable,
incorporation of ﬁndings from studies in addition to RESTORE,
such as the highly comparable DRCR study, provide very useful
data for answering critical questions relating to clinical practice
in a broad spectrum of patients with DME. It should be noted,
however, that some subgroups, such as patients with the
poorest glycaemic control (high glycated haemoglobin), were
excluded from these trials.
In conclusion, the results of our economic model show that
ranibizumab monotherapy is cost-effective relative to laser
therapy alone in the treatment of DME causing visual impair-
ment, while combined ranibizumab and laser therapy may be
cost-effective depending on patient characteristics. The cost-
effectiveness of ranibizumab monotherapy or combination
treatment is expected to be higher in younger patients who have
a longer life expectancy. These ﬁndings have important practical
implications, given the high socio-economic burden of DME
and the need for new, cost-effective treatments that reduce
long-term progression to blindness. Ongoing studies, such as
the RESTORE extension, will provide additional clariﬁcation
of current uncertainties such as the need for ranibizumab
injections after 2 years and the likelihood of recurrent DME.
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